COPD- pulmonary hyperinflation- the diaphragms are at the level of the eleventh posterior ribs and appear flat.
|
|
- Griselda Gray
- 6 years ago
- Views:
Transcription
1 COPD
2 COPD Hallmark symptom - Dyspnea Chronic productive cough Minor hemoptysis pink puffer blue bloater
3 COPD- pulmonary hyperinflation- the diaphragms are at the level of the eleventh posterior ribs and appear flat.
4 COPD - Physical Findings Tachypnea Accessory respiratory muscle use Pursed lip exhalation Weight loss due to poor dietary intake and excessive caloric expenditure for work of breathing
5
6 Dominant Clinical Forms of COPD Pulmonary y emphysema Chronic bronchitis Most patients exhibit a mixture of symptoms and signs
7 COPD - Advanced Dx secondary yp polycythemia y cyanosis tremor somnolence and confusion due to hypercarbia Secondary pulmonary HTN w or w/o cor pulmonale l
8 COPD Treatment Strategy Elimination of extrinsic irritants bronchodilator h t & glucocorticoid id therapy Antibiotics Mobilization of secretions respiratory vaccines Oxygen therapy - if oxygen saturation <90 90% at rest on room air
9 Spirometry
10
11 A-a gradient A-a gradient = predicted po 2 observed PO 2 PAO 2 = (FIO 2 X 713) (PaCO 2 /0.8) at sealevel PAO 2 = 150-(PaCO 2 /0.8) at sealevel on room air Normal range 10-15mm > 30 years of age Normal range 8mm < 30 years of age Increased A-aDO 2 =diffusion defect Right to left shunt V/Q mismatch
12 Examples A doubel overdose brings two 30 yr old patients to the ED. Both have ingested substantial amounts of barbiturates and diazepam. Blood gases drawn on room air revealed these values: patient 1- ph = , PCO 2 = 70mmHg, PO 2 =50mmHg, HCO 3 =24mEq/L; patient2- ph = , PCO 2 =50mmHg, PO 2 =50 50mmHg, HCO 3 =25 25mEq/L
13 Comment The A-a gradient calculation for patient 1 is as follows: A-a ado 2 = PAO 2 PaO 2 PAO 2 = 150 (1.25x PCO 2 ) PAO 2 = 150 (1.25x 70) PAO 2 = 62 A-a =62 50 A-a = 12
14 Comment The calculation reveals a normal gradient, indicating that the etiology for hypoxemia and hypoventilation is extrinsic to the lung itself.
15 Comment The A-a gradient calculation for patient 2 is as follows: PAO 2 = 150 (1.25 xpco) 2 PAO = 150 (1.25 x 50) 2 PAO 2 = PAO 2 = 87 Therefore,, A-a = =37 (an abnormally increased gradient)
16 Comment We can be reasonably confident that patient 1 suffered hypoventilation due to the effect of the ingested drugs on the brain stem. Temporary mechanical ventilation restored this patient s gas exchange.
17 Comment Patient 2, on the other hand, had an increased A-a gradient, indicating a lung problem in addition to any central cause for hypoventilation. The chest x-ray film revealed that this patient s t overdose was complicated by aspiration pneumonitis and that the patient required treatment with antibiotics in addition to mechanical ca ventilation.
18 COPD (Chronic Obstructive Pulmonary Disease) Chronic Bronchitis Emphysema
19 Definition A A disease state characterized by airflow limitation that is not fully reversible Conditions include: Emphysema: (anatomically defined condition characterized by destruction and enlargement of the lung alveoli) Chronic bronchitis: clinically defined condition with chronic cough and phlegm Small-airways airways disease: condition in which small bronchioles are narrowed
20 Epidemiology Fourth leading cause of death in the U.S. Affects > 16 million persons in the U.S. Global l Initiative for Chronic Obstructive ti Lung Disease (GOLD) estimates suggest that chronic obstructive lung disease (COLD) will increase from the sixth to the third most common cause of death worldwide by 2020.
21 Epidemiology >70 70% of COLD-related health care expenditures go to emergency department visits and hospital care (>$10 billion annually in the U.S.).
22 Epidemiology Sex Higher prevalence in men, probably secondary to smoking Prevalence of COLD among women is increasing as the gender gap in smoking rates has diminished.
23 Epidemiology i Age Higher prevalence with increasing age Dose response relationship between cigarette smoking intensity and decreased pulmonary function
24 Risk Factors 1. Cigarette smoking is a major risk factor. 2. Cigar and pipe smoking 3. Passive (secondhand) smoking Associated with reductions in pulmonary function Its status as a risk factor for COLD remains uncertain
25 Occupational exposures to dust and fumes (e.g., cadmium) Likely risk factors The magnitude of these effects appears substantially less important than the effect of cigarette smoking. Ambient t air pollution The relationship of air pollution to COLD remains unproven.
26 Genetic factors α1 antitrypsin (α1at) deficiency Common M allele: normal levels S allele: slightly reduced levels Z allele: markedly reduced levels Null allele: e absence of α1at (rare) (ae) Lowest levels of α1at are associated with incidence of COLD; α1at deficiency interacts with cigarette smoking to increase risk.
27 Distributions of forced expiratory volume in 1 s (FEV1)values in a general population p sample, stratified by yp pack-years of smoking
28 Etiology COLD Causal relationship between cigarette smoking and development of COLD has been proven: however, the response varies considerably among individuals.
29 COLD exacerbation Bacterial infections Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis Mycoplasma pneumoniae or Chlamydia pneumoniae (5 10% of exacerbations) Viral infections (one-third) No specific precipitant identified (20 35%)
30 Symptoms & Signs 3 most common: Cough Sputum production Exertional dyspnea, frequently of long duration
31 signs and symptoms Dyspnea at rest Prolonged expiratory phase and/or expiratory wheezing on lung examination Decreased breath sounds Barrel chest Large lung volumes and poor diaphragmatic excursion, as assessed by percussion Use of accessory muscles of respiration Pursed lip breathing (predominantly emphysema) Characteristic "tripod" sitting position to facilitate the actions of the sternocleidomastoid, scalene, and intercostal muscles Cyanosis, visible in lips and nail beds
32 Systemic wasting Significant weight loss Bitemporal wasting Diffuse loss of subcutaneous adipose tissue Paradoxical respiration Inward movement of the rib cage with inspiration (Hoover's sign) in some patients "Pink puffers" are patients with predominant emphysema no cyanosis or edema, with decreased breath sounds. "Blue bloaters" are patients with predominant bronchitis cyanosis cyanosis and edema. Most patients have elements of each.
33 Advanced disease: signs of cor pulmonale Elevated jugular venous distention Right ventricular heave Third heart sound Hepatic congestion Ascites Peripheral edema
34 Differential Diagnosis 1. Congestive heart failure 2. Asthma 3. Bronchiectasis 4. Obliterative bronchiolitis 5. Pneumonia 6. Tuberculosis 7. Atelectasis 8. Pneumothorax 9. Pulmonary embolism
35 Considerations 1. COLD is present only if chronic airflow obstruction occurs. Chronic bronchitis without chronic airflow obstruction is not COLD. 2. Asthma Reduced forced expiratory volume in 1 second (FEV1) in COLD seldom shows large responses (>30%) to inhaled bronchodilators, although improvements up to 15% are common. Asthma patients can also develop chronic (not fully reversible) airflow obstruction.
36 Considerations 3. Problems other than COLD should be suspected when hypoxemia is difficult to correct with modest levels of supplemental oxygen. 4. Lung cancer Clubbing of the digits it is not a sign of COLD.In patients with COLD, development of lung cancer is the most likely explanation for newly developed clubbing.
37 Chronic Bronchitis Chronic lower airway inflammation Increased bronchial mucus production Productive cough Urban male smokers > 30 years old
38 Chronic Bronchitis Mucus, swelling interfere with ventilation Increased CO 2, decreased 0 2 Cyanosis occurs early in disease Lung disease overworks right ventricle Right heart failure occurs RHF produces peripheral edema Blue Bloater
39 Emphysema Loss of elasticity in small airways Destruction of alveolar walls Ub Urban male smokers > years old
40 Emphysema Lungs lose elastic recoil Retain CO 2, maintain near normal O 2 Cyanosis occurs late in disease Barrel chest (increased AP diameter) Thin, wasted Prolonged exhalation through pursed lips Pink Puffer
41 COPD Management Oxygen Monitor carefully Some COPD patients may experience respiratory depression on high concentration oxygen Assist ventilations as needed
42 Diagnostic Approach Initial assessment 1. History and physical examination (Signs & Symptoms) 2. Pulmonary function testing to assess airflow obstruction 3. Radiographic studies
43 Assessment of exacerbation 1. History Fever Change in quantity and character of sputum ill contacts Associated symptoms Frequency and severity of prior exacerbations
44 Assessment of exacerbation 2. Physical examination Tachycardia Tachypnea Chest examination Focal findings Air movement Symmetry Presence or absence of wheezing Paradoxical movement of abdominal wall Use of accessory muscles Perioral or peripheral cyanosis Ability to speak in complete sentences Mental status
45 3. Radiographic studies Chest radiography focal findings (pneumonia, atelectasis) t 4. Arterial blood gases Hypoxemia Hypercapnia p 5. Hospitalization recommended for: Respiratory acidosis and hypercarbia Significant hypoxemia Severe underlying disease Living situation not conducive to careful observation and delivery of prescribed treatment
46 ABG and oximetry Although not sensitive, they may demonstrate resting or exertional hypoxemia. Blood gases provide additional information about alveolar ventilation and acid base status by measuring arterial PCO 2 and ph. Change in ph with PCO 2 is units/10 mmhg acutely and units/10 mmhg in the chronic state.
47 Laboratory Tests 1. Elevated hematocrit suggests chronic hypoxemia. 2. Serum level of α1at should be measured in some patients. o Presenting at 50 years of age o Strong family history o Predominant basilar disease o Minimal smoking history o Definitive diagnosis of α1at deficiency requires PI type determination. Typically performed by isoelectric focusing of serum, which reflects the genotype at the PI locus for the common alleles and many of the rare PI alleles Molecular genotyping can be performed for the common PI alleles (M, S, and Z). 3. Sputum gram stain and culture (for COLD exacerbation)
48 Imaging Chest radiography Emphysema: obvious bullae, paucity of parenchymal markings, or hyperlucency Hyperinflation: increased lung volumes, flattening of diaphragm Chest CT Does not indicate chronicity of changes Definitive test for establishing the diagnosis of emphysema, but not necessary to make the diagnosis
49 Pulmonary function tests/spirometry Diagnostic Procedures Chronically reduced ratio of FEV1 to forced vital capacity (FVC) In contrast to asthma, the reduced FEV1 in COLD seldom shows large responses (>30%) to inhaled bronchodilators, although improvements up to 15% are common. Reduction in forced expiratory flow rates Increases in residual volume Increases in ratio of residual volume to total lung capacity Increased total lung capacity (late in the disease) Diffusion capacity may be decreased in patients with emphysema. Electrocardiography d t t i f t i l h t h
50 Classification GOLD stage Classification based on pathologic type
51 GOLD stage 0 I II III IV Severity: at risk Symptoms: chronic cough, sputum production Spirometry: normal Severity: mild Symptoms: with or without chronic cough or sputum production Spirometry: FEV1:FVC < 0.7 and FEV1 80% predicted Severity: moderate Symptoms: with or without chronic cough or sputum production Spirometry: FEV1:FVC < 0.7 and FEV % predicted Severity: severe Symptoms: with or without chronic cough or sputum production Spirometry: FEV1:FVC < 0.7 and FEV % predicted Severity: very severe Symptoms: with or without chronic cough or sputum production Spirometry: FEV1:FVC < 0.7 and FEV1 < 30% predicted or FEV1 < 50% predicted with respiratory failure or signs of right heart failure
52 Treatment Approach General Only 2 interventions ti have been demonstrated t d to influence the natural history. Smoking cessation Oxygen therapy in chronically hypoxemic patients All other current therapies are directed at improving symptoms and decreasing frequency and severity of exacerbations. Therapeutic response should determine continuation of treatment.
53 Specific Treatments Stable-phase COLD, pharmacotherapy Bronchodilators Used to treat symptoms The inhaled route is preferred. Side effects are less than with parenteral delivery. Theophyllline: various dosages and preparations; p typical dose mg/d, adjusted based on levels
54 Specific Treatments Stable-phase COLD, pharmacotherapy Anticholinergic agents Trial of inhaled anticholinergics is recommended in symptomatic patients. Side effects are minor. Improve symptoms and produce acute improvement in FEV Do not influence rate of decline in lung function Ipratropium bromide (short-acting anticholinergic) (Atrovent) Inhaled: 30-min onset of action; 4-h duration Atrovent: metered-dose dose inhaler; 18 μg per i h l ti 1 2 i h l ti id
55 Specific Treatments Stable-phase COLD, pharmacotherapy Tiotropium op u (long-acting g anticholinergic) c) (Spiriva) Spiriva: powder via handihaler; 18 μg per inhalation; 1 inhalation qd Symptomatic benefit Long Long-acting inhaled β-agonists, such as salmeterol, have benefits similar to ipratropium bromide. More convenient than short-acting
56 Specific Treatments Stable-phase COLD, pharmacotherapy Addition of a β-agonist to inhaled anticholinergic therapy provides incremental benefit. Side effects Tremor Tachycardia Salmetrol l (Serevent): Powder via diskus; 50-μg inhalation every 12 h Formoterol (Foradil): Powder via aerolizer; 12 μg inhalation every 12
57 Specific Treatments Stable-phase COLD, pharmacotherapy Albuterol (short-acting β-agonist) (Proventil HFA, Ventolin HFA, Ventolin, Proventil) Metered-dose dose inhaler (or in nebulizer solution); 180-μg inhalation every 4 6 h as needed Combined β-agonist/anticholinergic: albuterol/ipratropium (Combivent) Metered-dose dose inhaler (also available in nebulizer solution); 120 mcg/21 μg
58 Specific Treatments Stable-phase COLD, pharmacotherapy Inhaled glucocorticoids Reduce frequency of exacerbations by 25 30% No evidence of a beneficial effect for the regular use of inhaled glucocorticoids on the rate of decline of lung function, as assessed by FEV1 Consider a trial in patients with frequent exacerbations ( 2 per year) and those who demonstrate a significant amount of acute reversibility in response to inhaled bronchodilators.
59 Specific Treatments Stable-phase COLD, pharmacotherapy Beclomethasone (QVAR): Metered-dose dose inhaler; μg/spray; μg bid Budesonide (Pulmicort): Powder via Turbuhaler; 200 μg/spray; 200 μg inhaled bid Fluticasone (Flovent): Metered-dose dose inhaler; 44, 110 or 220 μg/spray; μg inhaled bid Ti i l (A t)
60 Oxygen 1. Supplemental l O2 is the only therapy demonstrated to decrease mortality 2. In resting hypoxemia (resting O2 saturation < 88% or < 90% with signs of pulmonary hypertension or right heart failure), the use of O2 has been demonstrated to significantly affect mortality. 3. Supplemental O2 is commonly prescribed for patients with exertional hypoxemia or nocturnal hypoxemia. The rationale for supplemental O2 in these settings is physiologically sound, but benefits are not well substantiated.
61 Beclomethasone (QVAR): Metered-dose dose inhaler; μg/spray; μg bid Budesonide (Pulmicort): Powder via Turbuhaler; 200 μg/spray; 200 μg inhaled bid Fluticasone (Flovent): Metered-dose dose inhaler; 44, 110 or 220 μg/spray; μg inhaled bid Triamcinolone (Azmacort) Metered-dose dose inhaler via built-in in spacer; 100 μg/spray; / μg inhaled bid
62 Parenteral corticosteroids Long-term use of oral glucocorticoids id is not recommended. Side effects Osteoporosis, fracture Weight gain Cataracts Glucose intolerance Increased risk of infection Patients tapered off long-term low-dose prednisone (~10 mg/d) did not experience any adverse effect on the frequency of exacerbations, quality of life, or lung function. On average, patients lost ~4.5 kg (~10 lb) when steroids were withdrawn.
63 Theophylline Produces modest improvements in expiratory flow rates and vital capacity and a slight improvement in arterial oxygen and carbon dioxide levels in moderate to severe COPD Side effects Nausea (common) Tachycardia Tremor
64 Specific Treatments Stable-phase COLD, pharmacotherapy Oh Other agents 1. N-acetyl cysteine Used for its mucolytic and antioxidant (current clinical trials) properties 2. Intravenous α1at augmentation therapy for patients with severe α1at deficiency 3. Antibiotics Long-term suppressive or "rotating" ti " antibiotics are not beneficial
65 Specific Treatments Stable-phase COLD, nonpharmacologic therapies Smoking cessation All patients with COLD should be strongly urged to quit and educated about the benefit of cessation and risks of continuation. Combining gp pharmacotherapy py with traditional supportive approaches considerably enhances the chances of successful smoking cessation. Bupropion Nicotine replacement (gum, transdermal, inhaler, nasal spray) The U.S. Surgeon General recommendation is for all smokers considering quitting to be offered pharmacotherapy in the absence of any contraindication.
66 Specific Treatments Stable-phase COLD, nonpharmacologic therapies General medical care 1. Annual influenza vaccine 2. Polyvalent pneumococcal vaccine is recommended, although proof of efficacy in COLD patients is not definitive.
67 Specific Treatments Stable-phase COLD, nonpharmacologic therapies Pulmonary rehabilitation Improves health-related quality of life, dyspnea, and exercise capacity Rates of hospitalization are reduced over 6 to 12 months.
68 Specific Treatments Stable-phase COLD, nonpharmacologic therapies Lung volume reduction surgery Produces symptomatic and functional benefit in selected patients Emphysema Predominant upper lobe involvement Contraindications Significant pleural disease (pulmonary artery systolic pressure >45 mm Hg) Extreme deconditioning Congestive heart failure Other severe comorbid conditions FEV1 < 20% of predicted and diffusely distributed emphysema on CT or diffusing capacity for CO <20%
69 Specific Treatments Stable-phase COLD, nonpharmacologic therapies Lung transplantation COLD is the leading indication. Candidates 65 years Severe disability despite maximal medical therapy No comorbid conditions, such as liver, renal, or cardiac disease Anatomic distribution tion of emphysema and presence of pulmonary hypertension are not contraindications
70 exacerbation of COPD The goals of emergency therapy correct tissue oxygenation alleviate reversible bronchospasm treat the underlying etiology of the exacerbation
71 Administer controlled oxygen therapy correct or prevent life-threatening hypoxemia, PaO2 greater than 60 mm Hg or an SaO2 greater than 90 percent Improvement after administration of supplemental l oxygen may take 20 to 30 min to achieve a steady state
72 B 2-Agonists and anticholinergic agents are first-line therapies in the management of acute, severe COPD
73 CORTICOSTEROIDS short course (7 to 14 days) of systemic steroids appears more effective than placebo in improving FEV1 in acute severe exacerbations of COPD, role in mild-to to-moderate exacerbations Hyperglycemia is the most common adverse effect
74 ANTIBIOTICS All current guidelines recommend antibiotics if there is evidence of infection, change in volume of sputum and increased purulence of sputum benefits are more apparent in more severe exacerbations Antibiotic choices should be directed at the most common pathogens known to be associated with COPD exacerbation Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis duration of treatment;(3 to 14 days )
75 METHYLXANTHINES theophylline and aminophylline severe exacerbation when other therapy has failed or in patients already using methylxanthines who have subtherapeutic drug levels The bronchodilation effect of aminophylline is limited, therapeutic range is narrow
76 IV loading dose 5 to 6 mg/kg usually required to obtain an initial serum concentration of 8 to 12 macg/ml In patients who regularly use theophylline, a mini-loading dose should be administered: (target concentration currently currently assayed concentration) x volume of distribution (i.e., 0.5 times ideal body weight in liters) target concentration should be between 10 and 15 macg/ml. IV maintenance infusion rate is 0.2 to 0.8 mg/kg g ideal body weight per h. lower maintenance rates (congestive heart failure or hepatic insufficiency ) raise maintenance rates in patients with higher clearance rates, such as smokers
77 Summary for ED Management Assess severity of symptom Administer controlled oxygen therapy Perform arterial blood gas measurement after min if SaO2 remains <90% or if concerned about symptomatic hypercapnia
78 Administer bronchodilators B2-agonists and/or anticholinergic i agents by nebulization or MDI with spacer Consider adding intravenous methylxanthine, if needed Add corticosteroids ( Oral or intravenous) Consider antibiotics If increased sputum volume, change in sputum color, fever, or suspicion of infectious etiology of exacerbation
79 Laboratory y evaluation Chest x-ray CBC with differential Electrolytes Arterial blood gases ECG as needed
80 At all times Monitor fluid balance Consider subcutaneous heparin (venous thrombosis prophylaxis) Identify and treat associated conditions (e.g., heart failure, arrhythmias) Closely monitor condition of the patient
81 Indications for Invasive Mechanical Ventilation Severe dyspnea with use of accessory muscles and paradoxical abdominal motion Respiratory frequency >35 breaths per min Life-threatening hypoxemia: PaO2 <50 mm Hg (<5.3 kpa) or PaO2/FIO /FIO2 <200 mm Hg Severe acidosis (ph < ) and hypercapnia (PaCO2 >60 mm Hg or >8.0 kpa) Respiratory arrest Somnolence, impaired mental status Cardiovascular complications (hypotension, shock, heart failure) NIPPV failure
82 Indications for ICU Severe dyspnea that responds inadequately to initial emergency therapy Confusion, lethargy, coma Persistent or worsening hypoxemia: PaO2 <50 mm Hg (<6.7 kpa) Severe or worsening hypercapnia: PaCO2 >70 mm Hg (>9.3 kpa) Severe or worsening respiratory acidosis (ph <7.30) despite supplemental oxygen and NIPPV
83 Indications for Hospital Admission Marked increase in intensity of symptoms, such as sudden development of resting dyspnea Severe background of COPD Onset of new physical signs (e.g., cyanosis, peripheral edema) Failure of exacerbation to respond to initial medical management Significant comorbidities Newly occurring arrhythmias Diagnostic uncertainty Older age Insufficient home support
84 discharge to home (1) adequate supply of home oxygen, if needed (2) adequate and appropriate bronchodilator treatment (3) short course of oral corticosteroids (4) a follow-up with their physician
85 Spacer Devices for Metered Dose Inhalers Spacer devices have a chamber that receives the aerosol before it is inhaled. They serve two functions: a) to overcome e difficulties in coordinating the timing of the inhaler actuation and inhalation, b) to slow down the speed of delivery of the aerosol into the mouth so that less of the drug impacts in the throat.
86 Prevention Smoking prevention or cessation Prevention of exacerbations Long-term suppressive antibiotics are not beneficial. Inhalation glucocorticoids id should be considered in patients with frequent exacerbations or in patients with an asthmatic component. Vaccination against influenza and pneumococcal infection
Chronic Obstructive Pulmonary Disease
Scope of Problem Chronic Obstructive Pulmonary Disease Marianne J. Davies, RN, MSN, APRN Yale University School of Medicine Yale Comprehensive Cancer Center Nevada Cancer Institute 2005 Hospitalizations
More informationLecture Notes. Chapter 4: Chronic Obstructive Pulmonary Disease (COPD)
Lecture Notes Chapter 4: Chronic Obstructive Pulmonary Disease (COPD) Objectives Define COPD Estimate incidence of COPD in the US Define factors associated with onset of COPD Describe the clinical features
More informationChronic Obstructive Pulmonary Disease (COPD) Clinical Guideline
Chronic Obstructive Pulmonary Disease (COPD) Clinical These clinical guidelines are designed to assist clinicians by providing an analytical framework for the evaluation and treatment of patients. They
More informationChronic Obstructive Pulmonary Disease (COPD) Copyright 2014 by Mosby, an imprint of Elsevier Inc.
Chronic Obstructive Pulmonary Disease () 8.18.18 Copyright 2014 by Mosby, an imprint of Elsevier Inc. Description Airflow limitation not fully reversible progressive Abnormal inflammatory response of lungs
More informationCOPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.
1 Definition of COPD: COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. Airflow obstruction may be accompanied by airway hyper-responsiveness
More informationCOPD. Helen Suen & Lexi Smith
COPD Helen Suen & Lexi Smith What is COPD? Chronic obstructive pulmonary disease: a non reversible, long term lung disease Characterized by progressively limited airflow and an inability to perform full
More informationCOPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
More informationCOPD exacerbation. Chiara Maruggi, PGY2
COPD exacerbation Chiara Maruggi, PGY2 Learning objectives At the end of this lecture students will be able to: 1) Critically assess patients for COPD and design a management plan. 2) Develop a step-wise
More informationLecture Notes. Chapter 3: Asthma
Lecture Notes Chapter 3: Asthma Objectives Define asthma and status asthmaticus List the potential causes of asthma attacks Describe the effect of asthma attacks on lung function List the clinical features
More information2/12/2015. ASTHMA & COPD The Yin &Yang. Asthma General Information. Asthma General Information
ASTHMA & COPD The Yin &Yang Arizona State Association of Physician Assistants March 6, 2015 Sedona, Arizona Randy D. Danielsen, PhD, PA-C, DFAAPA Dean & Professor A.T. Still University Asthma General Information
More informationCOPD. Dr.O.Paknejad Pulmonologist Shariati Hospital TUMS
IN THE NAME OF GOD COPD Dr.O.Paknejad Pulmonologist Shariati Hospital TUMS Definition of COPD* COPD is a preventable and treatable chronic lung disease characterized by airflow limitation that is not fully
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationBasic mechanisms disturbing lung function and gas exchange
Basic mechanisms disturbing lung function and gas exchange Blagoi Marinov, MD, PhD Pathophysiology Department, Medical University of Plovdiv Respiratory system 1 Control of breathing Structure of the lungs
More informationCOPD Management in LTC: Presented By: Jessica Denney RRT
COPD Management in LTC: Presented By: Jessica Denney RRT Sponsored by Z & D Medical Services, Diamond Sponsor Seizing Opportunities to Provide Individualized Treatment and Device Selection for your COPD
More informationYou ve come a long way, baby.
COPD Dr Badri Paudel Dept of Medicine GMC/CHRC 4/22/12 badri@gmc 2 You ve come a long way, baby. Wayne McLaren Former Marlboro Man 4/22/12 badri@gmc 3 Age 30 a robust young man Age 51 riding into the sunset
More informationPulmonary Pathophysiology
Pulmonary Pathophysiology 1 Reduction of Pulmonary Function 1. Inadequate blood flow to the lungs hypoperfusion 2. Inadequate air flow to the alveoli - hypoventilation 2 Signs and Symptoms of Pulmonary
More informationCOPD. Stan Kellar, MD. Physiology 11/4/2014. Chief of Clinical Affairs, BH NLR Pulmonary Medicine Sleep Medicine
Stan Kellar, MD Chief of Clinical Affairs, BH NLR Pulmonary Medicine Sleep Medicine COPD Physiology The lungs are filters Filter in oxygen Filter out carbon dioxide (Vascular filter, not part of this discussion)
More informationIntegrated Cardiopulmonary Pharmacology Third Edition
Integrated Cardiopulmonary Pharmacology Third Edition Chapter 13 Pharmacologic Management of Asthma, Chronic Bronchitis, and Emphysema Multimedia Directory Slide 7 Slide 12 Slide 60 COPD Video Passive
More informationMedications for Managing COPD in Hospice Patients. Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources
Medications for Managing COPD in Hospice Patients Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources Goal of medications in COPD Decrease symptoms and/or complications Reduce frequency
More informationChronic obstructive lung disease. Dr/Rehab F.Gwada
Chronic obstructive lung disease Dr/Rehab F.Gwada Obstructive lung diseases Problem is in the expiratory phase Lung disease Restrictive lung disease Restriction may be with, or within the chest wall Problem
More informationChronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease 07 Contributor Dr David Tan Hsien Yung Definition, Diagnosis and Risk Factors for (COPD) Differential Diagnoses Goals of Management Management of COPD THERAPY AT EACH
More informationOver the last several years various national and
Recommendations for the Management of COPD* Gary T. Ferguson, MD, FCCP Three sets of guidelines for the management of COPD that are widely recognized (from the European Respiratory Society [ERS], American
More informationChronic Obstructive Pulmonary Disease
136 PHYSIOLOGY CASES AND PROBLEMS Case 24 Chronic Obstructive Pulmonary Disease Bernice Betweiler is a 73-year-old retired seamstress who has never been married. She worked in the alterations department
More informationParamedic Rounds. Pre-Hospital Continuous Positive Airway Pressure (CPAP)
Paramedic Rounds Pre-Hospital Continuous Positive Airway Pressure (CPAP) Morgan Hillier MD Class of 2011 Dr. Mike Peddle Assistant Medical Director SWORBHP Objectives Outline evidence for pre-hospital
More informationPeople with asthma who smoke. The combination of asthma, a chronic airway disease, and smoking increases the risk of COPD even more.
COPD Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Symptoms include breathing difficulty, cough, sputum (phlegm) production
More information2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters
GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized
More informationChronic obstructive pulmonary disease
Chronic obstructive pulmonary disease By: Dr. Fatima Makee AL-Hakak () University of kerbala College of nursing Out lines What is the? Overview Causes of Symptoms of What's the difference between and asthma?
More informationDifferential diagnosis
Differential diagnosis The onset of COPD is insidious. Pathological changes may begin years before symptoms appear. The major differential diagnosis is asthma, and in some cases, a clear distinction between
More informationManagement of Acute Exacerbations
15 Management of Acute Exacerbations Cenk Kirakli Izmir Dr. Suat Seren Chest Diseases and Surgery Training Hospital Turkey 1. Introduction American Thoracic Society (ATS) and European Respiratory Society
More informationPulmonary Pearls. Medical Pearls. Case 1: Case 1 (cont.): Case 1: What is the Most Likely Diagnosis? Case 1 (cont.):
Pulmonary Pearls Christopher H. Fanta, MD Pulmonary and Critical Care Division Brigham and Women s Hospital Partners Asthma Center Harvard Medical School Medical Pearls Definition: Medical fact that is
More informationHow to treat COPD? What is the mechanism of dyspnea? Smoking cessation
: The Increasing Role of the FP Alan Kaplan, MD, CCFP(EM) Presented at the Primary Care Today: Education Conference and Medical Exposition, Toronto, Ontario, May 2006. Chronic obstructive pulmonary disease
More informationan inflammation of the bronchial tubes
BRONCHITIS DEFINITION Bronchitis is an inflammation of the bronchial tubes (or bronchi), which are the air passages that extend from the trachea into the small airways and alveoli. Triggers may be infectious
More informationGOALS AND INSTRUCTIONAL OBJECTIVES
October 4-7, 2004 Respiratory GOALS: GOALS AND INSTRUCTIONAL OBJECTIVES By the end of the week, the first quarter student will have an in-depth understanding of the diagnoses listed under Primary Diagnoses
More informationCourse Handouts & Disclosure
COPD: Disease Trajectory and Hospice Eligibility Terri L. Maxwell PhD, APRN VP, Strategic Initiatives Weatherbee Resources Hospice Education Network Course Handouts & Disclosure To download presentation
More informationCOPD/Asthma. Prudence Twigg, AGNP
COPD/Asthma Prudence Twigg, AGNP COPD/Asthma Qualifying Diagnosis Known diagnosis of COPD/asthma or CXR showing COPD with hyperinflated lungs and no infiltrates + two or more: Wheezing, SOB, increased
More informationHOSPITAL RECORD ABSTRACTION FORM
HOSPITAL RECORD ABSTRACTION FORM ID NUMBER: VERSION: A 10/23/2015 0a. Form Completion Date... / / 0b. Staff Code... 0c. Event ID: 0d. Event Date: / / Instructions: Answers are derived from the medical
More informationRespiratory Disease. Dr Amal Damrah consultant Neonatologist and Paediatrician
Respiratory Disease Dr Amal Damrah consultant Neonatologist and Paediatrician Signs and Symptoms of Respiratory Diseases Cardinal Symptoms Cough Sputum Hemoptysis Dyspnea Wheezes Chest pain Signs and Symptoms
More informationCOPD. Definitionn. make. when (bronchioles) in. the lungs. Wheezing Chest tightness. your lungs. greenish. Lack of energy
COPD Definitionn Emphysema and chronic bronchitis are the two most common conditions thatt make up COPD. Chronic bronchitis is an inflammation of the lining of your bronchial tubes, which carry air to
More informationVA/DoD Clinical Practice Guideline Management of COPD Pocket Guide
VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide MODULE A: MAAGEMET OF COPD 1 2 Patient with suspected or confirmed COPD presents to primary care [ A ] See sidebar A Perform brief clinical
More informationChronic Obstructive Pulmonary Disease:
Chronic Obstructive Pulmonary Disease: THE BASICS PROF.G.E. ERHABOR Consultant Chest Physician Obafemi Awolowo University Teaching Hospital Complex, Ile-Ife, Nigeria. 1 BASICS IS THE ESSENCE OF GREATNESS,
More informationCOPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms
COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and
More informationAdvances in Chronic Obstructive Pulmonary Disease
Advances in Chronic Obstructive Pulmonary Disease By Dave C. Todd, MD; and Darcy D. Marciniuk, MD, FRCPC The case of Nina Nina, 64, presents to the clinic with a three- to fouryear history of progressive,
More informationMedications Affecting The Respiratory System
Medications Affecting The Respiratory System Overview Asthma is a chronic inflammatory disorder of the airways. It is an intermittent and reversible airflow obstruction that affects the bronchioles. The
More information& Guidelines. For The Management Of. Chronic Obstructive Air Way Disease (COPD)
Guidelines For The Management Of Chronic Obstructive Air Way Disease (COPD) By Dr. Sinan Butrus F.I.C.M.S Clinical Standards & Guidelines Dr.Layla Al-Shahrabani F.R.C.P (UK) Director of Clinical Affairs
More informationGuideline for the Diagnosis and Management of COPD
Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially
More informationAuthor(s): Frank Madore (Hennepin County Medical Center), MD 2012
Project: Ghana Emergency Medicine Collaborative Document Title: COPD in the Emergency Department Author(s): Frank Madore (Hennepin County Medical Center), MD 2012 License: Unless otherwise noted, this
More informationCOPD. Diseases and Conditions
Diseases and Conditions COPD By Mayo Clinic Staff Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Symptoms include breathing
More informationUpdate on heterogeneity of COPD, evaluation of COPD severity and exacerbation
Update on heterogeneity of COPD, evaluation of COPD severity and exacerbation Yung-Yang Liu, MD Taipei Veterans General Hospital Aug 29, 2015 G O lobal Initiative for Chronic bstructive L D ung isease
More informationII: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical
Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%
More information1 Chapter 13 Respiratory Emergencies 2 Respiratory Distress Patients often complain about. Shortness of breath Symptom of many different Cause can be
1 Chapter 13 Respiratory Emergencies 2 Respiratory Distress Patients often complain about. Shortness of breath Symptom of many different Cause can be difficult to determine. Even for physician in hospital
More informationFunction of the Respiratory System. Exchange CO2 (on expiration) for O2 (on inspiration)
Function of the Respiratory System Exchange CO2 (on expiration) for O2 (on inspiration) Upper Respiratory Tract Includes: Nose Mouth Pharynx Larynx Function: Warms and humidifies the inspired air Filters
More informationProvider Respiratory Inservice
Provider Respiratory Inservice 2 Welcome Opening Remarks We will cover: Definition of Asthma & COPD Evidence based guidelines for diagnosis, evaluation, and management of asthma Evidence based guidelines
More informationTreatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1
58 COPD 59 The treatment of COPD includes drug therapy, surgery, exercise and counselling/psychological support. When managing COPD patients, it is particularly important to evaluate the social and family
More informationChronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease CareOregon Pharmacy Abridged sample of presentation content Home Equipment Pathophysiology Exacerbations Guidelines Lifestyle Modification Medication Management Sample
More informationRespiratory Emergencies. Chapter 11
Respiratory Emergencies Chapter 11 Respiratory System Anatomy and Function of the Lung Characteristics of Adequate Breathing Normal rate and depth Regular breathing pattern Good breath sounds on both sides
More informationSample Case Study. The patient was a 77-year-old female who arrived to the emergency room on
Sample Case Study The patient was a 77-year-old female who arrived to the emergency room on February 25 th with a chief complaint of shortness of breath and a deteriorating pulmonary status along with
More informationAssessing Severity. Management of Stable COPD. General Approach. Short Acting Bronchodilators. Staging System (GOLD)
William P. Saliski Jr. DO Montgomery Pulmonary Consultants Management of Stable COPD Pharmacotherapy Oxygen Smoking Cessation Vaccinations Rehabilitation Surgery Future Discussions Assessing Severity Staging
More informationFirefighter Pre-Hospital Care Program Recruit Presentation. Respiratory Emergencies
Firefighter Pre-Hospital Care Program Recruit Presentation Respiratory Emergencies The Respiratory System Anatomy Pharynx Nasopharynx Oropharynx Epiglottis Larynx Trachea Right main bronchus Left main
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More informationLearning Objective. Asthma. Discuss the pathophysiology, clinical presentation, diagnosis, and treatment of Asthma 2/22/2017
Marianne Curran, PA C 3/1/17 Learning Objective Discuss the pathophysiology, clinical presentation, diagnosis, and treatment of Definition many variations Chronic Disorder with Reversible (Intermittent
More informationOverview of COPD INTRODUCTION
Overview of COPD INTRODUCTION Chronic obstructive pulmonary disease (COPD) is a common lung disease that affects millions of people, and it is the fourth leading cause of death in the United States. It
More informationCOPD exacerbation. Dr. med. Frank Rassouli
Definition according to GOLD report: - «An acute event - characterized by a worsening of the patients respiratory symptoms - that is beyond normal day-to-day variations - and leads to a change in medication»
More informationQuestion by Question (QXQ) Instructions for the Pulmonary Diagnosis Form (PLD)
Question by Question (QXQ) Instructions for the Pulmonary Diagnosis Form (PLD) A Pulmonary Diagnosis Form is filled out by the reviewer for all medical records that are sent to them for review by the CSCC.
More informationCOPD Challenge CASE PRESENTATION
Chronic obstructive pulmonary disease (COPD) exacerbations may make up more than 10% of acute medical admissions [1], and they are increasingly recognised as a cause of significant morbidity and mortality
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MOUSTAPHA ABIDALI, DO CRITICAL CARE FELLOW UNIVERSITY OF ARIZONA- PHOENIX
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MOUSTAPHA ABIDALI, DO CRITICAL CARE FELLOW UNIVERSITY OF ARIZONA- PHOENIX COPD OUTLINE Definition and Overview Pathophysiology Diagnosis and Assessment Therapeutic
More informationRespiratory Diseases and Disorders
Chapter 9 Respiratory Diseases and Disorders Anatomy and Physiology Chest, lungs, and conducting airways Two parts: Upper respiratory system consists of nose, mouth, sinuses, pharynx, and larynx Lower
More informationCOPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
More informationCOPD/ Asthma. Dr Heather Lewis Honorary Clinical Lecturer
COPD/ Asthma Dr Heather Lewis Honorary Clinical Lecturer Objectives To understand the pathogenesis of asthma/ COPD To recognise the clinical features of asthma/ COPD To know how to diagnose asthma/ COPD
More informationHistory & Development
RSPT 2317 Anticholinergic Bronchodilators () History & Development Prototypical parasympatholytic agent is atropine an alkaloid found naturally in the plants Atropa belladona (nightshade) and Datura species
More informationChronic Obstructive Lung Disease - Dr. Kawa Chronic Bronchitis & Emphysema
Chronic Obstructive Lung Disease - Dr. Kawa Chronic Bronchitis & Emphysema COPD Definition COPD is a chronic, slowly progressive disorder characterized by airflow obstruction. (FEV1 is less than 80% of
More informationWomen Beware-The Threat of COPD
Page 1 Speaker: Catherine Cooke attained her Bachelor in Pharmacy from the University of Iowa and then went on to receive her Pharm.D. from the Medical University of South Carolina. Subsequently, she completed
More informationASTHMA. Epidemiology. Pathophysiology. Diagnosis. IAP UG Teaching slides
BRONCHIAL ASTHMA ASTHMA Epidemiology Pathophysiology Diagnosis 2 CHILDHOOD ASTHMA Childhood bronchial asthma is characterized by Airway obstruction which is reversible Airway inflammation Airway hyper
More informationAcute respiratory failure
Rita Williams, NP-C, PA PeaceHealth Medical Group Pulmonary & Critical Care Acute respiratory failure Ventilation/perfusion mismatching Most common cause of hypoxemia Normal is 1:1 ratio or 1 Ventilation
More informationJOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES
JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE
CHRONIC OBSTRUCTIVE PULMONARY DISEASE DEFINITION Chronic obstructive pulmonary disease (COPD) is a common preventable and treatable disease characterized by airflow limitation that is usually progressive
More informationChronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Symptoms include breathing difficulty, cough, sputum (phlegm) production
More informationRESPIRATORY EMERGENCIES. Michael Waters MD April 2004
RESPIRATORY EMERGENCIES Michael Waters MD April 2004 ASTHMA Asthma is a chronic inflammatory disease of the airways with variable or reversible airway obstruction Characterized by increased sensitivity
More informationWomen Beware The Threat of COPD
Page 1 Women Beware The Threat of COPD Catherine E. Cooke, PharmD, BCPS, PAHM President, PosiHealth, Inc. & Clinical Associate Professor, University of Maryland School of Pharmacy Supported by an education
More informationof COPD Wayne Kradjan, Pharm. D. Dean and Professor Oregon State University College of Pharmacy
Pathophysiology and Treatment of COPD Wayne Kradjan, Pharm. D. y j, Dean and Professor Oregon State University College of Pharmacy COPD Consensus Statementst t Global Initiative for Chronic Obstructive
More informationCPAP. Pre-Hospital Treatment Using The Respironics Whisperflow CPAP Device. Charlottesville Albemarle Rescue Squad - CPAP
CPAP Pre-Hospital Treatment Using The Respironics Whisperflow CPAP Device CPAP What Is It? C ontinuous P ositive A irway P ressure Anatomy Review Anatomy Review Anatomy Review Alveoli Anatomy Review Chest
More informationCOPD. Yesterday and Today; Achievements and Challenges. Zurab Gurul MD, PhD
COPD Yesterday and Today; Achievements and Challenges Zurab Gurul MD, PhD The history of COPD The evolution of knowledge concerning COPD and its components emphysema, chronic bronchitis, and asthmatic
More informationObjectives. Health care significance of ARF 9/10/15 TREATMENT OF ACUTE RESPIRATORY FAILURE OF VARIABLE CAUSES: INVASIVE VS. NON- INVASIVE VENTILATION
TREATMENT OF ACUTE RESPIRATORY FAILURE OF VARIABLE CAUSES: INVASIVE VS. NON- INVASIVE VENTILATION Louisa Chika Ikpeama, DNP, CCRN, ACNP-BC Objectives Identify health care significance of acute respiratory
More informationPresented by UIC College of Nursing
Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long-acting inhalers and emergency use inhalers.
More informationChronic Obstructive Pulmonary Disease 1/18/2018
Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long acting inhalers and emergency use inhalers.
More informationPulmonary Function Testing: Concepts and Clinical Applications. Potential Conflict Of Interest. Objectives. Rationale: Why Test?
Pulmonary Function Testing: Concepts and Clinical Applications David M Systrom, MD Potential Conflict Of Interest Nothing to disclose pertinent to this presentation BRIGHAM AND WOMEN S HOSPITAL Harvard
More informationChronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC
Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC I have no financial disclosures Definition COPD is a preventable and treatable disease
More informationChronic Obstructive Pulmonary Disease Guidelines and updates
Chronic Obstructive Pulmonary Disease Guidelines and updates October 20, 2018 Saratoga Springs, NY COPD (Chronic obstructive pulmonary disease) is a major cause of mortality and morbidity in the United
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
Page 1 of 9 PURPOSE To assure that DOP inmates with Pulmonary Diseases are receiving high quality Primary Care for their condition. POLICY All DOP Primary Care Providers and Chronic Disease Nurses are
More informationRespiratory Medicine
Respiratory Medicine This document is based on the handout from the Medicine for Finals course. The notes provided here summarise key aspects, focusing on areas that are popular in clinical examinations.
More informationChronic Obstructive Pulmonary Disease (COPD).
Chronic Obstructive Pulmonary Disease (COPD). Linde: Living healthcare 02 03 Chronic Obstructive Pulmonary Disease (COPD). A pocket guide for healthcare professionals. COPD the facts Moderate to severe
More informationChronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
More informationOPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING 10/16/2018 DISCLOSURES I have no financial or other disclosures
OPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING J. Michael Fuller, MD, MEd, FACP, FCCP Associate Professor of Medicine University of South Carolina Greenville DISCLOSURES I have no financial or other
More informationChronic Obstructive Pulmonary Disease
Supportive module 3 "Basics of diagnosis, treatment and prevention of major pulmonary diseases " Chronic Obstructive Pulmonary Disease LECTURE IN INTERNAL MEDICINE FOR IV COURSE STUDENTS M. Yabluchansky,
More informationChronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease (COPD) Definition of COPD Airflow obstruction that is: o Not fully reversible o Progressive o Does not change markedly over several months Combination of airway and
More informationRespiratory Failure. Causes of Acute Respiratory Failure (ARF): a- Intrapulmonary:
Respiratory failure exists whenever the exchange of O 2 for CO 2 in the lungs cannot keep up with the rate of O 2 consumption & CO 2 production in the cells of the body. This results in a fall in arterial
More informationLecture Notes. Chapter 2: Introduction to Respiratory Failure
Lecture Notes Chapter 2: Introduction to Respiratory Failure Objectives Define respiratory failure, ventilatory failure, and oxygenation failure List the causes of respiratory failure Describe the effects
More informationCOPD Diagnosis, Management and Program
COPD Diagnosis, Management and Program RYAN MARTIN, MD NEBRASKA PULMONARY SPECIALTIES Initial diagnosis Setting matters: Inpatient. Usually sicker, oftentimes avoiding healthcare. Outpatient. Often seeking
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy f the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationTLALELETSO. Chronic Lung Disease
dates for your practice June, 2013. Vol 2, Issue 18 TLALELETSO Chronic Lung Disease This issue is focused on chronic lung disease. We discuss diagnosis, management and prevention, focusing on the importance
More informationRespiratory Pharmacology
Allergy Targets of allergies Type I Histamine Leukotrienes Prostaglandins Bradykinin Hypersensitivity reactions Asthma Characterised by Triggered by Intrinsic Extrinsic (allergic) Mediators Result Early
More information